ArticleOrthopaedic journal of sports medicine2026
No Added Benefit of Nonsteroidal Anti-Inflammatory Drug Prophylaxis Beyond 15 Days for Heterotopic Ossification After Hip Arthroscopy.
Article in Orthopaedic journal of sports medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heterotopic ossification (HO) is a well-known postoperative complication of hip arthroscopy that can lead to pain, limited range of motion, and, in advanced cases, the need for revision surgery. Nonsteroidal anti-inflammatory drugs (NSAIDs), including diclofenac and indomethacin, are widely used for HO prophylaxis. However, there is no consensus on the optimal agent, dosage, and duration of administration. Hypothesis/Purpose: This study aims to compare the efficacy of diclofenac and indomethacin administered for different durations in preventing HO after hip arthroscopy and to evaluate the impact of varying treatment regimens on postoperative clinical outcomes. It was hypothesized that both diclofenac and indomethacin would effectively prevent HO, with no significant difference in HO incidence between them or with prolonged treatment. Study Design: Cohort study; Level of evidence, 3. Methods: A retrospective, multicenter study included 1084 patients who underwent hip arthroscopy for femoroacetabular impingement (FAI) between January 2017 and December 2024. Patients were categorized according to the prophylaxis protocol administered: diclofenac 75 mg for 15 days or indomethacin 75 mg for 15, 30, or 45 days daily. The presence and grade of HO were evaluated according to the Brooker classification. Functional outcomes were assessed pre- and 3, 6, 9, and 12 months postoperatively using the visual analog scale for pain (VAS-Pain) and the Hip Outcome Score-Activities of Daily Living (HOS-ADL). Results: No significant difference in HO development was observed among the study groups ( Conclusion: The incidence and severity of HO did not differ significantly among diclofenac and indomethacin prophylaxis regimens after hip arthroscopy. Prolonging indomethacin prophylaxis beyond 15 days was not associated with a lower rate of HO. These findings suggest that longer NSAID prophylaxis protocols may not provide additional benefit for HO prevention compared with shorter regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.